Opportunistic salpingectomy (OS), which is the removal of fallopian tubes during hysterectomy or instead of tubal ligation without removal of ovaries, is recommended to prevent ovarian cancer, particularly serous ovarian cancer. However, the effectiveness of OS is still undetermined.

**OBJECTIVE** To examine observed vs expected rates of ovarian cancer among individuals who have undergone OS.

**DESIGN, SETTING, AND PARTICIPANTS** This is a population-based, retrospective cohort study of all individuals in British Columbia, Canada, who underwent OS or a control surgery (hysterectomy alone or tubal ligation) between 2008 and 2017, with follow-up until December 31, 2017. Those with any gynecological cancer diagnosed before or within 6 months of their procedure were excluded. Data analysis was performed from April to August 2021.

**EXPOSURES** Removal of both fallopian tubes at the time of hysterectomy or instead of tubal ligation while leaving ovaries intact.

**MAIN OUTCOMES AND MEASURES** An ovarian cancer diagnosis listed in the British Columbia Cancer Registry. Age-specific rates of epithelial and serous ovarian cancer in the control group were combined with the specific follow-up time in the OS group to calculate expected numbers (and 95% CIs) of ovarian cancers in the OS group. These were compared with observed numbers. Age-adjusted expected and observed numbers of breast and colorectal cancers were also examined in the OS group.

**RESULTS** There were 25,889 individuals who underwent OS (mean [SD] age, 40.2 [7.1] years; median [IQR] follow-up, 3.2 [1.6-5.1] years) and 32,080 who underwent hysterectomy alone or tubal ligation (mean [SD] age, 38.2 [7.9] years; median [IQR] follow-up, 7.3 [4.6-8.7] years). There were no serous ovarian cancers in the OS group and 5 or fewer epithelial ovarian cancers. The age-adjusted expected number was 5.27 (95% CI, 1.78-19.29) serous cancers and 8.68 (95% CI, 3.36-26.58) epithelial ovarian cancers. Age-adjusted expected vs observed numbers of breast cancers (22.1 expected vs 23 observed) and colorectal cancers (9.35 expected vs 8 observed) were not significantly different.

**CONCLUSIONS AND RELEVANCE** In this cohort study, the OS group had significantly fewer serous and epithelial ovarian cancers than were expected according to the rate at which they arose in the control group. These findings suggest that OS is associated with reduced ovarian cancer risk.
Introduction

Approximately 70% of sporadic and nearly all ovarian cancers in **BRCA** variant carriers are high-grade serous carcinomas (HGSCs),¹ which is the most lethal of the 5 main histotypes and has a 5-year survival rate less than 50%.² Although the general population lifetime risk of ovarian cancer is 1.4%,³ individuals with an inherited germline **BRCA1** or **BRCA2** variant have average cumulative risks of 40% to 75% and 8% to 34%, respectively.⁴ In **BRCA** 1/2 variant carriers, bilateral salpingo-oophorectomy is recommended, which reduces the risk of ovarian or fallopian tube cancers by 80%.⁵ Removal of the ovaries is not recommended for the general population because it is associated with increased total mortality, coronary heart disease, and osteoporosis.⁶ Thus, a different preventive strategy is needed for individuals at average risk, who account for 80% of cases of HGSCs.

The recent understanding that HGSC often originates in the fallopian tube⁷,⁸ has led to a primary prevention opportunity for the general population—namely, opportunistic salpingectomy (OS). OS collectively refers to the removal of the fallopian tubes at the time of hysterectomy or instead of tubal ligation, while leaving the ovaries intact. In 2010, the British Columbia (BC) ovarian cancer research team launched a province-wide strategy asking gynecologists to discuss OS with their patients as an ovarian cancer prevention strategy. The same recommendation has since been made in many countries, including Canada, the US, and the UK for individuals without identified genetic factors associated with increased risk of ovarian cancer.⁹-¹² Research has shown that OS is safe, both in terms of perioperative adverse events¹³ and minor complications,¹⁴ there are no indications of an earlier age of onset of menopause following OS,¹⁵ and it is cost-effective.¹⁶

Some retrospective data from individuals who underwent bilateral salpingectomy for conditions such as hydrosalpinx and pelvic inflammatory disease have suggested decreased risk of ovarian cancer among individuals without fallopian tubes.¹⁷-¹⁹ However, we hypothesize that OS is associated with more protection than salpingectomies done for diseases that directly affect and distort the fallopian tube, because the intent of OS is complete removal of the fimbriated end of the fallopian tube, which may not occur when salpingectomy is done for other indications. Finally, these historical studies did not use the appropriate control groups, as OS is recommended only for individuals already undergoing gynecological surgery, and both hysterectomy and tubal ligation are associated with protection against ovarian cancer.²⁰ Here, we examine observed rates of ovarian cancer and compare these with expected rates (based on age-adjusted rates of ovarian cancer in the control group of individuals who underwent hysterectomy alone or tubal ligation).

Methods

This population-based, retrospective, cohort study examined data on all residents of the Canadian province of BC (population, 5 million). All individuals who underwent a hysterectomy or tubal sterilization in BC between 2008 and 2017 were included. Approvals were obtained from all relevant data stewards, and access to the Consolidation file, the BC Cancer Registry, the Discharge Abstract Database, and the BC Cancer Agency Screening Program was facilitated through Population Data BC. More details, including citations to data sources, are presented in the eTable in the Supplement.

Ethics approval was obtained from the University of British Columbia's Behavioral Research Ethics Board. Approval by the ethics board and the BC data stewards for use of deidentified administrative data files includes a waiver of informed consent from participants. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.²¹

Exposure

Individuals who underwent any of the relevant surgical procedures were identified using the Canadian Classification of Health Intervention codes. This system separately identifies each procedure performed during the same surgery, and a person undergoing a hysterectomy with
bilateral salpingectomy has both a code indicating the removal of the uterus and one indicating the removal of the fallopian tubes. Individuals with a diagnosis of any gynecological cancer before or within 6 months of their surgery were excluded, as this cancer was likely present at the time of surgery. Individuals were stratified into 2 groups according to their procedures: (1) those who underwent OS, meaning they had a hysterectomy with a salpingectomy but no oophorectomy, or they had a bilateral salpingectomy alone with a diagnosis code indicating the procedure was for sterilization (International Statistical Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] code Z.30.2), and (2) those who underwent control surgical procedures, which included those who had undergone a hysterectomy with no concomitant oophorectomy or salpingectomy and anyone who underwent a tubal ligation.

Outcome
In BC, cancer is a reportable disease, and all cases are entered into the provincial cancer registry. The registry sources include hematology and pathology reports, death certificates, hospital reports, and cancer treatments (see the eTable in the Supplement for more details). All ovarian cancers were identified using the International Classification of Diseases for Oncology (ICD-O) codes for ovarian cancer (ICD-O code C56.X), fallopian tube cancer (ICD-O code C57.0), or peritoneal cancer, not otherwise specified (ICD-O code C48.2). All epithelial ovarian cancers diagnosed after a surgery of interest were included, and borderline tumors were excluded. ICD-O morphology codes were used to identify the histotype of the ovarian cancers according to the algorithm published by Peres et al.22 The grade data were incomplete, and all serous cancers were presented together rather than as low grade and high grade; however, 95% of serous cancers are HGSCs. To examine whether differences in the observed and expected ovarian cancers in the OS group might be explained by underlying differences in the likelihood of getting cancer associated with health status, lifestyle, genetics, and so forth, differences in observed and age-adjusted expected numbers of breast cancer (ICD-O code C50) and colorectal cancer (ICD-O code C18.X) but excluding cancer of the appendix (ICD-O code C18.1) were also examined.

Potential Confounders
We examined how the groups differed with respect to potentially important confounders, including age at the time of surgery, income quintiles, parity, gravidity, history of oral contraceptive pill use and total mean days of oral contraceptive use, presence of a known BRCA variant, and the presence of benign gynecological conditions at the time of surgery, including endometriosis (ICD-10-CM code N80.X), leiomyoma (ICD-10-CM code D25.X), benign ovarian or uterine neoplasm (ICD-10-CM codes D26.X, D27.X, and D28.7), abnormal bleeding (ICD-10-CM codes N92.X and N93.X), pelvic organ prolapse (ICD-10-CM code N81.X), pelvic inflammatory disease (ICD-10-CM codes N73.X and N74.X), and hydrosalpinx (ICD-10-CM code N70.X).

Statistical Analysis
For privacy reasons, data steward agreements require that we not publish cell sizes between 1 and 5. The number of observed epithelial and serous ovarian cancers in the OS group are presented according to privacy requirements. We also present the number of observed breast and colorectal cancers. These observed numbers were then compared with the number expected on the basis of age-adjusted (in 5-year age groups) rates in the control group multiplied by the person-time contribution in the OS group. Given the low number of ovarian cancers in both groups, statistical models were not run. Instead the distribution of the potential confounders across the OS and control groups and their standardized differences were presented. A difference between covariates was considered meaningful if the standardized difference was greater than 0.1.23 The age-adjusted rates of serous ovarian cancers were also used to project the number of expected serous ovarian cancers in the OS group 5 and 10 years beyond our study period if serous ovarian cancers were to occur at the same rate as in the control group. To project, we used data from
the cohort included in our control group and adjusted the person-time contribution in each age group as individuals in the cohort age. Data were analyzed using Stata statistical software version 16 (StataCorp). Data analysis was performed from April to August 2021.

Results

Before exclusions, there were 60,153 individuals who underwent any of the surgical procedures of interest. After exclusion of 74 individuals who were younger than age 15 years at the time of surgery and 2110 individuals with cancers that were diagnosed before or within 6 months of surgery, there were 25,889 individuals (mean [SD] age, 40.2 [7.1] years) in the OS group, including 14,066 who underwent hysterectomy with OS and 11,823 who underwent OS for sterilization. There were 32,080 individuals (mean [SD] age, 38.2 [7.9] years) in the control group, including 10,446 individuals who underwent hysterectomy alone and 21,634 who underwent tubal ligation (Figure 1). The Table compares the characteristics of the OS groups (hysterectomy with OS and OS for sterilization) with the control groups (hysterectomy alone and tubal ligation). There were no meaningful differences in any oral contraceptive pill use (18,098 individuals [69.9%] in the OS group vs 21,414 individuals [66.8%] in the control group), duration of oral contraceptive pill use (OS group, mean [SD], 757 [109] days and median [IQR], 265 [0-1080] days; control group, mean [SD], 662 [965] days and median [IQR], 218 [0-960] days), and BRCA variant rates between the groups (27 individuals [0.10%] in the OS group vs 34 individuals [0.11%] in the control group). Individuals who underwent OS were older at the time of surgery (mean [SD], 40.2 [7.1] vs 38.2 [7.9] years), had fewer live births (mean [SD], 1.74 [1.29] vs 2.03 [1.33] live births) and fewer pregnancies (mean [SD], 2.26 [1.87] vs 2.63 [1.93] pregnancies), and were more likely to have endometriosis (3301 individuals [12.8%] vs 2279 individuals [7.1%]) than those in the control group. There was longer follow-up in the control group vs the OS group (median [IQR], 7.3 [4.6-8.7] vs 3.2 [1.6-5.1] years).

Figure 2 illustrates that there were no serous cancers in the OS group by the end of follow-up. Given the age-adjusted rate at which serous ovarian cancers occurred in the control group and the follow-up time in the OS group, 5.27 (95% CI, 1.78-19.29) serous cancers were expected. The same is true for all epithelial ovarian cancers. The expected number of epithelial ovarian cancers in the OS group was 8.68 (95% CI, 3.36-26.58) cancers, and the actual number was less than or equal to 5 (exact number not presented to protect patient privacy) (Figure 2B). In contrast, there were 15 serous cancers in the control group, and 21 epithelial ovarian cancers (including 6 nonserous cancers). Figures 2C and 2D show no significant differences between expected and observed numbers of breast or colorectal cancers in the OS group. The age-adjusted expected number of breast cancers in the OS group was 22.1 (95% CI, 11.62-49.37) cancers, and 23 breast cancers were observed in this group. The age-adjusted expected number of colorectal cancers in the OS group was 9.35 (95% CI, 3.13-30.11) cancers, and 8 cancers were observed.
Figure 3 shows projections of serous cancers in the OS group if they arise at the same rate as those in the control group. Because there were no serous cancers in the OS group, we cannot estimate exactly how many of these serous cancers will be prevented. If OS were not performed, we would expect an estimated 36.9 (95% CI, 12.2-127.7) serous cancers by 2022 and 45.1 (95% CI, 14.7-157.5) cancers by 2027. These numbers do not account for additional individuals being added to the OS group.

Discussion

The realization that the fallopian tube fimbriae is the tissue of origin for most HGSCs opened the door for OS as a primary ovarian cancer prevention strategy.8 Prevention of ovarian cancer seems more critical today than ever as the largest screening trial found that although a stage shift was achieved, there was no mortality benefit.24 In BC in 2010, a population-wide primary prevention campaign was initiated to remove the fallopian tubes of individuals at general population risk for ovarian cancer when they were undergoing hysterectomy for benign indications or seeking tubal ligation. The acceptability, safety, and cost-effectiveness of this OS campaign has already been established.13-16 In this cohort study, we now present data strongly suggesting that OS is effective as an ovarian cancer primary prevention strategy at the population level. There was not a single serous ovarian cancer in the OS group, which was significantly fewer than the slightly more than 5 that were expected. We have further shown that the OS group had the same risk of breast and colorectal cancers compared with the control group, indicating that the lack of ovarian cancers in the OS groups is unlikely to be associated with selection bias. The rates of common risk and protective factors for the OS group

Table. Characteristics of the Opportunistic Salpingectomy Group and Those Who Underwent Hysterectomy Alone or Tubal Ligation

| Characteristic                              | Hysterectomy alone or tubal ligation (n = 32 080) | Opportunistic salpingectomy (n = 25 889) | Standardized mean difference |
|--------------------------------------------|-----------------------------------------------|----------------------------------------|-----------------------------|
| Age at time of surgery, mean (SD), y       | 38.2 (7.9)                                    | 40.2 (7.1)                             | 0.2743                     |
| Duration of follow-up, median (IQR), y     | 7.3 (4.6-8.7)                                 | 3.2 (1.6-5.1)                          | 0.8987                     |
| Income quintile                            |                                               |                                        |                             |
| Patients, No.                              | 27 488                                        | 13 592                                 |                             |
| 1                                          | 5869 (21.4)                                   | 2718 (20.0)                            |                             |
| 2                                          | 6185 (22.5)                                   | 2782 (21.2)                            | 0.0675                     |
| 3                                          | 5769 (21.0)                                   | 2887 (21.2)                            |                             |
| 4                                          | 5327 (19.4)                                   | 2867 (21.1)                            |                             |
| 5                                          | 4338 (15.8)                                   | 2338 (17.2)                            |                             |
| Parity, live births, mean (SD), No.        | 2.03 (1.33)                                   | 1.74 (1.29)                            | 0.2239                     |
| Pregnancies, mean (SD), No.                | 2.63 (1.93)                                   | 2.26 (1.87)                            | 0.1965                     |
| Oral contraceptive pill use                | 21 414 (66.8)                                 | 18 098 (69.9)                          | 0.0678                     |
| Duration of oral contraceptive pill use, d  |                                               |                                        |                             |
| Mean (SD)                                  | 662 (965)                                     | 757 (1091)                             | 0.0923                     |
| Median (IQR)                               | 218 (0-960)                                   | 264 (0-1080)                           |                             |
| BRCA variant                               | 34 (0.11)                                     | 27 (0.10)                              | 0.0023                     |
| Endometriosis                              | 2279 (7.1)                                    | 3301 (12.8)                            | 0.1897                     |
| Uterine leiomyoma                          | 3760 (11.7)                                   | 6474 (25.0)                            | 0.3483                     |
| Benign uterine or ovarian neoplasm         | 225 (0.7)                                     | 355 (1.4)                              | 0.0661                     |
| Prolapse                                   | 2127 (6.6)                                    | 1314 (5.1)                             | 0.0663                     |
| Abnormal bleeding                          | 6919 (21.6)                                   | 9395 (36.3)                            | 0.3290                     |
| Pelvic inflammatory disease                | 606 (1.9)                                     | 746 (2.9)                              | 0.0628                     |
| Hydrosalpinx                               | 122 (0.4)                                     | 209 (0.8)                              | 0.0556                     |
| Polycystic ovary syndrome                  | 43 (0.1)                                      | 50 (0.19)                              | 0.0146                     |
place them at slightly higher risk of ovarian cancer (eg, lower parity, lower gravidity, and higher age), indicating that our results are unlikely to be explained by confounding.

There were 15 serous cancers observed in the control group, and our calculations show that as we continue follow-up, there will be 45.1 serous ovarian cancers in this group by 2027. It is difficult to determine the preventable fraction given that we did not observe any serous cancers in our OS group. The least conservative interpretation would be that OS prevents all serous cancers, but more

---

**Figure 2. Numbers of Expected vs Observed Cancers in the Opportunistic Salpingectomy Group**

![Graphs showing expected vs. observed cancers](image)

- **A** Serous cancer
- **B** Epithelial ovarian cancer
- **C** Breast cancer
- **D** Colorectal cancer

Error bars denote 95% CIs.

* Denotes a cell size of less than or equal to 5, not an exact number.

---

**Figure 3. Projected Expected Numbers of Serous Ovarian Cancers in the Opportunistic Salpingectomy Group**

![Projected numbers of serous ovarian cancers](image)

Error bars denote 95% CIs.
realistically it is probably more in line with the prevention achieved by risk-reducing salpingo-
oophorectomy in patients with a BRCA variant, which is on the order of 80%. For example, if an
estimated 200,000 individuals underwent hysterectomy without salpingectomy and a tubal ligation
(instead of an OS) in Canada between 2011 and 2016, then on the basis of a 1% lifetime risk of HGSC
and an assumed 80% effectiveness of OS, 1,600 future cases of HGSC could theoretically have been
prevented. Thus, although the numbers presented here are small, uptake of OS on a larger scale
could be associated with the incidence of HGSCs nationally and internationally.

These findings may also further our understanding of the origin for HGSCs. Twenty years ago in
a provocative editorial, it was suggested that the ovarian surface epithelium may not be the tissue
of origin for ovarian carcinomas. Shortly afterward, detailed analysis of fallopian tubes and ovaries
from BRCA variant carriers found tubal dysplastic lesions, now called serous tubal intraepithelial
carcinomas, but no ovarian pathology. Systematic analysis of fallopian tubes and ovaries in many
studies has since shown that serous tubal intraepithelial carcinomas are found in individuals with
BRCA variants, also alongside sporadic and incidental HGSCs but not in the general population.7,27,30
Genomic studies have confirmed the clonal association between serous tubal intraepithelial
carcinomas and HGSC, and transgenic mice with mutated fallopian tube cells produce histologically
perfect HGSCs.31,32 However, there are data supporting potential primary ovarian origins of some
HGSCs, including mouse models and expression data; thus, it is possible that some HGSCs arise from
ovarian surface epithelium or endosalpingiosis.33,34 However, despite detailed analysis in many
studies, credible ovarian HGSC precursors have not been described. Ultimately, expansion of the data
presented here will determine the relative portion of HGSCs that originate in the fallopian tube vs
the ovary.

Our findings are consistent with previous epidemiological research from the US, Denmark, and
Sweden,17,19 which studied the association between excisional tubal surgery or salpingectomy and
the risk of ovarian cancer among individuals with a medical indication for these procedures. The
observed relative risks showed a 42% to 65% reduction in risk of ovarian cancer for individuals who
underwent a major surgical procedure involving the fallopian tube.17,19 Furthermore, tubal ligation
has long been recognized as being inversely associated with ovarian cancer risk, although the
magnitude of the association is lower than those for the more extensive fallopian tube procedures
mentioned already.35

Limitations
Our work has some important limitations, including that these are observational data and not derived
from a randomized clinical trial; thus, selection factors could introduce bias. However, the Table
illuminates that there are few differences between the OS group and control group with respect to the
most well-known risk and protective factors for ovarian cancer (eg, parity, oral contraceptive pill use,
BRCA variant status, and endometriosis), and the differences that do exist would bias toward
increased risk for ovarian cancer in the OS group. Although it remains possible that there are
important unmeasured differences between the groups, such as lifestyle factors that are associated
with cancer, the findings of no difference between the observed and expected numbers of breast
and colorectal cancers in the OS group suggest that selection bias is unlikely to explain these results.
The study was limited by the small number of cancers and relatively short follow-up time in our
groups. Although uptake of OS has been substantial in BC, the province has a relatively small
population (approximately 5 million), and the surgical procedures at which OS is performed occur at
young mean ages. Thus, our numbers of ovarian cancers were small, making it impossible to run Cox
proportional hazards models controlling for potential confounders. In addition, although the
preliminary data suggest that there are no indicators of an earlier age of onset of menopause, it is
time to conduct a long-term follow-up study on the age of onset of menopause as self-reported by
those who undergo OS or a control surgery. Given the reduction in observed ovarian cancer
compared with expected, which strongly supports reduced risk of ovarian cancer following OS, it is
important to ensure OS does not alter the age of onset of menopause.
Conclusions

This study found significantly smaller numbers of observed ovarian cancers compared with expected numbers for patients who underwent prophylactic OS at the time of hysterectomy or instead of tubal ligation. Most professional gynecological societies around the world have recommended consideration of OS. Our findings strengthen the evidence for presenting this option to patients at average risk of ovarian cancer. These data may also aid in patient decision-making around contraception options following childbearing.

ARTICLE INFORMATION

Accepted for Publication: December 15, 2021.

Published: February 9, 2022. doi:10.1001/jamanetworkopen.2021.47343

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Hanley GE et al. JAMA Network Open.

Corresponding Author: Gillian E. Hanley, PhD, Vancouver General Hospital Research Pavilion, 590-828 W 10th Ave, Vancouver, BC V5Z 1M9, Canada (gillian.hanley@vch.ca).

Author Affiliations: Division of Gynaecologic Oncology, Department of Gynaecology and Obstetrics, The University of British Columbia, Vancouver, British Columbia, Canada (Hanley, Talhouk, Kwon, Finlayson, McAlpine, Huntsman, Miller); Vancouver General Hospital Research Pavilion, Vancouver, British Columbia, Canada (Hanley); Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor (Pearce); Pathology & Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada (Huntsman).

Author Contributions: Dr Hanley had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Huntsman and Miller are co–final authors and contributed equally to this work.

Concept and design: Hanley, Talhouk, Finlayson, McAlpine, Huntsman, Miller.

Acquisition, analysis, or interpretation of data: Hanley, Pearce, Kwon, McAlpine, Huntsman.

Drafting of the manuscript: Hanley, Kwon.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Hanley, Pearce, Talhouk, Kwon.

Obtained funding: Hanley, Talhouk, Finlayson.

Administrative, technical, or material support: Hanley, Finlayson, Miller.

Supervision: Kwon, McAlpine.

Conflict of Interest Disclosures: Dr Kwon reported receiving grants from Astra Zeneca outside the submitted work. No other disclosures were reported.

Funding/Support: This research was supported by funding from the Canadian Institutes of Health Research, the Janet D. Cottrelle foundation, and the Vancouver General Hospital and University of British Columbia Hospital Foundation. Dr Hanley is supported by a Canadian Institutes of Health Research New Investigator Award, a Michael Smith Foundation for Health Research Scholar award, the Canadian Cancer Society Research Institute, and is a Janet D. Cottrelle Foundation scholar.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: All inferences, opinions, and conclusions are those of the authors and do not reflect the opinions or policies of the Data Stewards.

Additional Contributions: We thank the general gynecologists in British Columbia, Canada, for enthusiastically following the 2010 recommendation for opportunistic salpingectomy. Without their support, this research would not have been possible.

Additional Information: Researchers can apply to access these data, available to any interested researchers through Population Data BC (http://www.popdata.bc.ca) following ethics approval, completion of a data access request, and approval of that data access request by all relevant data stewards.
REFERENCES

1. Schrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120(2, pt 1):235-240. doi:10.1097/AOG.0b013e31825f3576

2. Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(3):2785-2800. doi:10.1002/cncr.31551

3. Pearson CL, Stram DO, Ness RB, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24(4):671-676. doi:10.1158/1055-9965.EPI-14-1128

4. Mavaddat N, Peock S, Frost D, et al. EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812-822. doi:10.1093/jnci/djt095

5. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002;38(suppl):S15-S17. doi:10.1016/S0959-8049(02)00269-1

6. Eleje GU, Eke AC, Ezebiaku IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8:CD012464. doi:10.1002/14651858.CD012464.pub2

7. Kindelberger DW, Lee Y, Mirron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-169. doi:10.1097/01.pas.0000213335.40358.47

8. Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17(1):65-74. doi:10.1038/nrc.2016.113

9. American College of Obstetrics & Gynecology. Committee opinion no. 620: salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015;125(1):279-281. doi:10.1097/AOG.0000459871.88564.09

10. Royal College of Obstetricians & Gynecologists. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas: scientific impact paper No. 44. November 2014. Accessed January 6, 2022. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip44hgsccs.pdf

11. Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer. November 1, 2013. Accessed January 6, 2022. https://www.sgo.org/resources/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/

12. Salvador S, Scott S, Francis JA, Agrawal A, Giede C. No. 344—opportunistic salpingectomy and other methods of risk reduction for ovarian/fallopian tube/peritoneal cancer in the general population. J Obstet Gynaecol Can. 2017;39(6):480-493. doi:10.1016/j.jogc.2016.12.005

13. McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014;210(5):471.e1-471.e11. doi:10.1016/j.ajog.2014.01.003

14. Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. Am J Obstet Gynecol. 2018;219(2):172.e1-172.e8. doi:10.1016/j.ajog.2018.05.019

15. Hanley GE, Kwon JS, McAlpine JN, Huntsman DG, Finlayson SJ, Miller D. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. Am J Obstet Gynecol. 2020;222(2):e21-e24. doi:10.1016/j.ajog.2020.02.005

16. Kwon JS, McAlpine JN, Hanley GE, et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015;125(2):338-345. doi:10.1097/AOG.0000000000000630

17. Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015;107(2):dju410. doi:10.1093/jnci/dju410

18. Lessard-Anderson CR, Handlogten KS, Molitor RJ, et al. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2014;135(3):423-427. doi:10.1016/j.ygyno.2014.10.005

19. Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015;94(1):86-94. doi:10.1111/aogs.12516

20. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5(1):13. doi:10.1186/1757-2215-5-13

21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-1499. doi:10.1016/j.ijsu.2014.07.013
22. Peres LC, Cushing-Haugen KL, Købel M, et al. Invasive epithelial ovarian cancer survival by histotype and
disease stage. J Natl Cancer Inst. 2019;111(1):60-68. doi:10.1093/jnci/djy071
23. Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for
propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8)(suppl):S84-S90.e1.
doi:10.1016/j.jclinepi.2013.01.013
24. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-
term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Lancet. 2021;397(10290):2182-2193. doi:10.1016/S0140-6736(21)00731-5
25. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the
emperor have no clothes? Gynecol Oncol. 1999;72(3):437-442. doi:10.1006/gyno.1998.5275
26. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of
women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451-456. doi:10.1002/path.1000
27. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with
familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230-236. doi:10.1097/01.pas.0000180854.
28831.77
28. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of
serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1):127-132. doi:10.1200/JCO.2005.
O4.109
29. Tang S, Onuma K, Deb P, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic
malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol. 2012;31(2):103-110. doi:10.1097/PGP.
Ob013e31822ea955
30. Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation
carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011;4(3):463-470.
doi:10.1158/1940-6207.CAPR-09-0127
31. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube.
Nat Commun. 2017;8(1):1093. doi:10.1038/s41467-017-00962-1
32. Perets R, Wyant GA, Muto KW, et al. Transformation of the fallopian tube secretory epithelium leads to high-
grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24(6):751-765. doi:10.1016/j.ccr.2013.
10.013
33. Hao D, Li J, Jia S, et al. Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and
predicts differential therapeutic responses. Clin Cancer Res. 2017;23(23):7400-7411. doi:10.1158/1078-0432.CCR-
17-0638
34. Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA, Neel BG. Both fallopian tube and ovarian surface epithelium
are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun. 2019;10(1):5367. doi:10.1038/s41467-
019-13116-2
35. Sieh W, Salvador S, McGuire V, et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer
Study Group; Ovarian Cancer Association Consortium. Tubal ligation and risk of ovarian cancer subtypes: a pooled
analysis of case-control studies. Int J Epidemiol. 2013;42(2):579-589. doi:10.1093/ije/dyt042

SUPPLEMENT.

eTable. Additional Details From Registry Sources
eReferences